801-2, Jindong Mansion, No. 536 Xueshi Road, Yinzhou, Ningbo 315100, P.R.China
Home ProductsActive Pharmaceutical Ingredients

Anastrozole API Active Pharmaceutical Ingredients CAS 120511-73-1 High Purity

Anastrozole API Active Pharmaceutical Ingredients CAS 120511-73-1 High Purity

Anastrozole API Active Pharmaceutical Ingredients CAS 120511-73-1 High Purity

Product Details:

Place of Origin: China
Brand Name: Newlystar
Certification: GMP
Model Number: USP, BP

Payment & Shipping Terms:

Minimum Order Quantity: 25kg
Price: Negotiation
Packaging Details: 10kg, 25kg per carton
Delivery Time: 30days
Payment Terms: L/C, T/T
Supply Ability: Ten tons per month
Contact Now
Detailed Product Description
Product: Anastrozole API CAS NO.: 120511-73-1
Purity: 99.0% Usage: Anti Cancer

Anastrozole API Active Pharmaceutical Ingredients CAS 120511-73-1 High Purity

 

 

Anastrozole API

CAS NO. 120511-73-1

Purity : 99.0%

 

Description :

Anastrozole is a drug indicated in the treatment of breast cancer in post-menopausal women. It is used both in adjuvant therapy (i.e. following surgery) and in metastatic breast cancer. It decreases the amount of estrogens that the body makes. Anastrozole belongs in the class of drugs known as aromatase inhibitors. It inhibits the enzyme aromatase, which is responsible for converting androgens (produced by women in the adrenal glands) to estrogens.

 

Indication :

For adjuvant treatment of hormone receptor positive breast cancer , as well as hormonal treatment of advanced breast cancer in post-menopausal women. Has also been used to treat pubertal gynecomastia and McCune-Albright syndrome; however, manufacturer states that efficacy for these indications have not been established.


Pharmacodynamics :

Anastrozole is a potent and selective non-steroidal aromatase inhibitor indicated for the treatment of advanced breast cancer in post-menopausal women with disease progression following tamoxifen therapy. Many breast cancers have estrogen receptors and growth of these tumors can be stimulated by estrogens. In post-menopausal women, the principal source of circulating estrogen (primarily estradiol) is conversion of adrenally-generated androstenedione to estrone by aromatase in peripheral tissues, such as adipose tissue, with further conversion of estrone to estradiol. Many breast cancers also contain aromatase; the importance of tumor-generated estrogens is uncertain. Treatment of breast cancer has included efforts to decrease estrogen levels by ovariectomy premenopausally and by use of anti-estrogens and progestational agents both pre- and post-menopausally, and these interventions lead to decreased tumor mass or delayed progression of tumor growth in some women. Anastrozole is a potent and selective non-steroidal aromatase inhibitor. It significantly lowers serum estradiol concentrations and has no detectable effect on formation of adrenal corticosteroids or aldosterone.

 

Mechanism of action :

Anastrozole selectively inhibits aromatase. The principal source of circulating estrogen (primarily estradiol) is conversion of adrenally-generated androstenedione to estrone by aromatase in peripheral tissues. Therefore, aromatase inhibition leads to a decrease in serum and tumor concentration of estrogen, leading to a decreased tumor mass or delayed progression of tumor growth in some women. Anastrozole has no detectable effect on synthesis of adrenal corticosteroids, aldosterone, and thyroid hormone.

Contact Details
Newlystar (Ningbo) Medtech Co.,Ltd.

Contact Person: Luke Liu

Send your inquiry directly to us (0 / 3000)